Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

Fact checked by Nick Blackmer MASH, an advanced form of nonalcoholic fatty liver disease, refers to the inflammation of the ...

People with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, have limited ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Fatty liver disease occurs when more than 5-10% of the liver's weight is made up of fat. This can lead to inflammation in the ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) ...

Study highlights the role of the Nwd1 gene in liver disease, paving the way for new therapies and better liver health Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease ...

Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...